The berberine paradox — popular marketing, no authorised EFSA claims
The berberine paradox — popular marketing, no authorised EFSA claims
In 2023 and 2024, berberine became one of the most-discussed supplement ingredients on English-language social media. "Nature's Ozempic", "natural metformin", "the secret behind reversing pre-diabetes". The marketing was exuberant. At the same time, under the current European rules not a single health claim approved by EFSA is available for berberine.
This blog is about that discrepancy. It explains how the European rules for botanical supplement ingredients work, with berberine as a concrete example. It is not advice on whether berberine "works" — that question falls outside what a webshop blog may answer.
What berberine actually is
Berberine is an alkaloid — a plant compound with biological activity, comparable to other alkaloids such as caffeine, morphine and quinine. It is extracted from the roots and bark of Berberis aristata (Indian barberry), Berberis vulgaris, Hydrastis canadensis and Coptis chinensis.
In traditional Chinese herbal medicine and ayurveda, berberine has been used for more than 2,000 years — historically above all in a gastrointestinal context. On product pages a supplier may mention that traditional context, plus the botanical description and the composition of a standardised extract. That is permitted within the EU framework.
What EFSA has assessed — and rejected
Under European Regulation 1924/2006 (nutrition and health claims made on foods), several health claims have been submitted for berberine by manufacturers. Among others on:
- Cholesterol balance
- Blood sugar context
- Liver function
- Immune system
- Urinary tract
- Gastric function
- The restorative capacity of the skin
All submitted claims have been assessed by EFSA as scientifically insufficiently substantiated — rejected or parked as "on-hold". For a Dutch supplement supplier that means: these claims may not appear on the label or the product page, not even under an asterisk disclaimer "pending European authorisation". Since 2023 the NVWA has been enforcing this structurally.
That is an unusually complete rejection. For many other ingredients EFSA has granted some claims and rejected others. For berberine the position is: zero permitted claims as a single plant compound.
What this means in practice for a product page
| Text on a berberine product page | Permitted? |
|---|---|
| "Berberine for healthy cholesterol" | Not permitted |
| "Berberine supports blood sugar levels" | Not permitted |
| "Berberine supports liver function" | Not permitted |
| "Berberine activates AMPK" (mechanism claim) | Not permitted without recognised EFSA substantiation |
| "Clinically proven…" | Not permitted |
| "Berberine — alkaloid from Berberis aristata" (botanical description) | Permitted |
| "Standardised to 97% berberine salts" (composition) | Permitted |
| "Traditionally used in Chinese herbal medicine" (historical context) | Permitted |
| Dosage instructions + safety information | Permitted |
What remains on a compliant product page is therefore a factual description of the ingredient: what it is, where it comes from, what its composition is, how much you get per capsule, and which contraindications or medicines call for caution.
Why this is not merely marketing bureaucracy
EFSA's rejection of berberine claims is not a technical detail. The underlying principle is that a consumer should not be able to buy a product through marketing on the basis of something that behaves as a therapeutic promise. As soon as a product is promoted for a specific health purpose or application, it legally falls under medicines legislation — a far heavier requirement (registration, clinical trials, and so on).
The boundary between a food supplement and a medicine does not lie in the chemical composition — it lies in how it is promoted. A berberine capsule sold as "alkaloid extract from Berberis aristata, 500 mg per capsule, traditionally used" is a food supplement. The same capsule sold as "lowers cholesterol and blood sugar" would legally have to be treated as a medicine — which the supplier can almost certainly not carry.
How to read the marketing
Three signals that help you to make distinctions within a product range:
- Comparisons with pharmaceutical drugs ("natural metformin", "Nature's Ozempic"): claims that equate berberine with medicines overstate both the effect and the regulatory status. Walk on.
- "Clinically proven reduction of X" without a study citation or NVWA-compliant substantiation: breaches the rules. The supplier is taking a risk with your purchasing decision.
- A product page with nothing but a botanical description + composition + dosage + safety: that is what a compliant approach looks like. It says something about the culture of the brand.
The role of the personal conversation
What is not allowed on a product page is allowed in a personal conversation with a doctor, pharmacist or orthomolecular practitioner — within the legal framework. That is not a back door; it is exactly how the rules are intended. Marketing communication is strictly regulated; individual care conversations are not.
For anyone wondering whether a specific botanical ingredient — berberine or another — suits their individual situation, a consultation with a doctor or orthomolecular practitioner is the right place for that question. Not blog content, not a product page, not a customer service message.
Safety still belongs on the product page
Independently of the claims question, sound safety information belongs on a compliant product page. Berberine is a bioactive alkaloid with known drug interactions:
- Antidiabetics (metformin, sulphonylureas, insulin)
- Anticoagulants (warfarin, DOACs)
- CYP3A4 substrates (statins, ciclosporin, some antidepressants)
- Macrolide antibiotics (clarithromycin, erythromycin)
Do not use during pregnancy or breastfeeding. If you take medication, always consult a doctor or pharmacist beforehand. This safety information — separate from any claims about effects — does appear on a compliant product page, and belongs there.
Vitarium therapeutic editorial team
The berberine example illustrates how the European rules for botanical supplement ingredients work in practice: an ingredient can be sold as a botanical product with an honest description, composition and safety information — without a supplier making claims about effects that EFSA has not approved. For consumers this means that the product page of a supplier who keeps to the rules reads less spectacularly than a marketing-led alternative, and is considerably more reliable as a basis for a purchasing decision. For deeper questions about what botanical ingredients can mean in an individual situation, a consultation with a doctor or orthomolecular practitioner remains the appropriate route — not a webshop.
This article explains regulation and is not medical or supplementation advice. If you have personal questions about botanical supplements, drug interactions or metabolic context: consult a doctor or orthomolecular practitioner.
Sources: Regulation (EC) No 1924/2006 on nutrition and health claims made on foods · Regulation (EU) No 432/2012 (list of permitted health claims) · EFSA Health Claim Register — rejected berberine claims · NVWA annual enforcement reports on food supplements 2023–2025.